Irlandia - angielski - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; nitrogen; sodium chloride - for use in the treatment of metastatic nonseminomatous germ cell carcinoma, advanced stage refractory ovarian carcinoma, advanced stage refractory bladder carcinoma and refractory squamous cell carcinoma of the head and neck, either singularly or in combination with other chemotherapeutic agents; or in appropriate circumstances, in addition to other treatments, such as radiotherapy or surgery.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - cisplatin intas may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Australia - angielski - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - cisplatin intas may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinomama,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Australia - angielski - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - cisplatin intas may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Australia - angielski - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium chloride; sodium hydroxide - cisplatin intas may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cisplatin 1 mg/ml;   - solution for injection - 1 mg/ml - active: cisplatin 1 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - cisplatin accord injection is indicated for the palliative treatment of: · metastatic non-seminomatous germ cell carcinoma; · advanced-stage refractory ovarian carcinoma; · advanced-stage refractory bladder carcinoma; and · refractory squamous cell carcinoma of the head and neck. it may be used as a single agent or in combination with other chemotherapeutic agents. it may be employed, in appropriate circumstances, in addition to other modalities, e.g. radiotherapy or surgery.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

bluepoint laboratories - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin injection is indicated as therapy to be employed as follows: metastatic testicular tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. metastatic ovarian tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. advanced bladder cancer cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existing renal impairment. cisplatin should not be employed in myelosuppressed patients, or in patients with hearing impairment. cisplatin is contraindicated in patients with a history of allergic reactions to cisplatin or other platinum-containing compounds.